Ad
related to: dhp calcium channel blocker contraindications
Search results
Results from the WOW.Com Content Network
Compared with certain other L-type calcium channel blockers (for example those of the phenylalkylamine class such as verapamil) that have significant action at the heart, the dihydropyridine calcium channel blockers lower blood pressure mainly by relaxing the smooth muscle of the blood vessel walls. [3]
Dihydropyridine (DHP) calcium channel blockers are derived from the molecule dihydropyridine and often used to reduce systemic vascular resistance and arterial pressure. Sometimes when they are used to treat angina , the vasodilation and hypotension can lead to reflex tachycardia , which can be detrimental for patients with ischemic symptoms ...
Calcium channel blockers (CCBs) preferentially block the L-type voltage-gated calcium channels to prevent the flow of calcium influx in the blood vessels and the heart, thereby reducing peripheral vascular resistance and cardiac output respectively. [10] Dihydropyridines (DHP): amlodipine, nifedipine, felodipine, nicardipine
Efonidipine is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels. [1] Drug Controller General of India (DCGI) has approved the use of efonidipine in India. [2]
1,4-Dihydropyridine (DHP) is an organic compound with the formula CH 2 (CH=CH) 2 NH. The parent compound is uncommon, [ 2 ] but derivatives of 1,4-dihydropyridine are important commercially and biologically.
Nisoldipine is a pharmaceutical drug used for the treatment of chronic angina pectoris and hypertension.It is a calcium channel blocker of the dihydropyridine class. It is sold in the United States under the proprietary name Sular.
Clevidipine is a dihydropyridine L-type calcium channel blocker, highly selective for vascular, as opposed to myocardial, smooth muscle and, therefore, has little or no effect on myocardial contractility or cardiac conduction. It reduces mean arterial blood pressure by decreasing systemic vascular resistance.
Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. It was patented in 1978 and approved for medical use in 1989. [1]
Ad
related to: dhp calcium channel blocker contraindications